Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $15.5200 (-1.21%) ($15.3000 - $15.8500) on Wed. Feb. 12, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.98% (three month average) | RSI | 71 | Latest Price | $15.5200(-1.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(60%) IBB(59%) ARKK(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -2.49% in a week (0% probabilities). VIXM(-41%) VXX(-40%) TLT(-8%) UUP(-6%) SHY(0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.49% (StdDev 4.98%) | Hourly BBV | 0 () | Intraday Trend | -1.6% | | | |
|
5 Day Moving Average | $15.62(-0.64%) | 10 Day Moving Average | $15.23(1.9%) | 20 Day Moving Average | $14.56(6.59%) | To recent high | -2% | To recent low | 118% | Market Cap | $1.966b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |